科济药业中期业绩显示，期内股东应占亏损3.52亿元，同比收窄13.08%。公告称，收益主要来自赛恺泽 (泽沃基奥仑赛注射液，自体BCMA CAR-T细胞产品)，其中赛恺泽的主要收入是以出厂价格进行计算的，而不是以终端市场价进行计算的。集团的收益于完成产品的出厂交付后确认。此外，截至2024年6月30 日止六个月，公司就赛恺泽从华东医药获得里程碑付款7500万元。由于CAR-T生产存在必需的时间周期，从华东医药获得的订单数量与出厂交付的数差量存在异。Keji Pharmaceutical-B (02171) rose more than 13%. As of press release, it rose 12.67% to HK$5.07, with a turnover of HK$28.1184 million.
The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose by more than 13%. As of press release, it had risen 12.67% to HK$5.07, with a turnover of HK$28.1184 million.
According to the news, Koji Pharmaceuticals announced that the US Food and Drug Administration recently reviewed the company's production site in Durham, North Carolina. The company passed this inspection with zero defects. The company submitted a full response to the FDA on October 4, requesting the cancellation of clinical trials of Zevokiolensae injection, Scherichiolenol injection, and CT071. The FDA is expected to respond within 30 calendar days.
The interim results of Keji Pharmaceutical showed that shareholders should have accounted for a loss of 0.352 billion yuan during the period, a year-on-year decrease of 13.08%. According to the announcement, the revenue mainly comes from Sekaiser (Zewokie Orense injection, autologous BCMA CAR-T cell product). Among them, Seckeiser's main revenue is calculated at factory prices rather than terminal market prices. The Group's earnings are confirmed upon completion of the delivery of the product from the factory. Furthermore, for the six months ended June 30, 2024, the company received a milestone payment of 75 million yuan from Huadong Pharmaceutical for Cykaize. Due to the required time cycle for CAR-T production, there is a difference between the number of orders received from Huadong Pharmaceutical and the number delivered from the factory.
